Clinical.Info 2024 : Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV

The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV document is published in an electronic format and updated as relevant changes in prevention and treatment recommendations occur.

All changes are developed by the subject-matter groups listed in the document. (Changes in group composition also are posted promptly.) These changes are reviewed by the editors and relevant outside reviewers before the document is altered. Major revisions within the last 6 months are as follows:

May 2, 2024

Mycobacterium tuberculosis

• Recommended a 4-month regimen of daily rifapentine, isoniazid, pyrazinamide, and moxifloxacin as an alternative treatment for active pulmonary tuberculosis (TB) in people receiving efavirenz-based antiretroviral therapy.
• Recommended a regimen consisting of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) as the preferred treatment for rifampin-resistant TB.

Additional information to the following link: HIV Clinical Guidelines: Adult and Adolescent Opportunistic Infections - What's New in the Guidelines | Clinicalinfo.HIV.gov